All relevant data are within the paper and its Supporting Information file. In addition, the raw data from miRNA-array analysis are provided in NCBI's Gene Expression Omnibus (GEO; Series accession number GSE57570; <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE57570>).

Introduction {#sec001}
============

Under steady state conditions, hematopoietic stem and progenitor cells (HSPCs) reside quiescent in their bone marrow niche \[[@pone.0128231.ref001]\]. However, they possess the potential to greatly increase proliferation and self-renewal if required---e.g. after high dose chemotherapy followed by hematopoietic stem cell transplantation (HSCT) \[[@pone.0128231.ref002]\]. Hematopoietic reconstitution after allogeneic or autologous HSCT is usually observed within weeks, but it is still unclear which signals recruit the HSPCs into action \[[@pone.0128231.ref003]\]. In a previous study, we demonstrated that systemically released factors in patient serum after HSCT contribute to this regulatory process \[[@pone.0128231.ref004]\]. We identified growth factors which change in serum upon chemotherapy, e.g. three isoforms of platelet-derived growth factor (PDGF), leukemia inhibitory factor (LIF), chemokine \[C-X-C motif\] ligand 10 (IP-10) and chemokine \[C-C motif\] ligand 2 (MCP-1), but none of them seemed to be relevant as a unique signaling factor. Despite the common perception that growth factors play a leading role in hematopoietic regulation, there might be other mechanisms involved such as microRNAs (miRNAs) or metabolites.

MicroRNAs are short, non-coding RNAs that regulate gene expression at the post-transcriptional level by binding to target mRNAs and thereby either inhibiting their translation or accelerating their degradation \[[@pone.0128231.ref005]\]. Beside their intracellular localization, miRNAs have recently been found to circulate in blood and various other body fluids and their expression changes according to physiological and pathological conditions \[[@pone.0128231.ref006],[@pone.0128231.ref007]\]. It is conceivable that such circulating miRNAs are actively secreted to mediate signaling effects. Little is known about the origin of miRNAs circulating in serum, but they may be predominantly secreted by blood cells \[[@pone.0128231.ref008]\]. To prevent RNA degradation and to target miRNAs to the recipient, miRNAs can be packed into microvesicles, such as exosomes \[[@pone.0128231.ref009]\], or they can be associated with high-density lipoproteins \[[@pone.0128231.ref010]\]. These microvesicles or lipoprotein-miRNA complexes have been shown to be taken up by recipient cells via endocytosis---and hence circulating miRNAs can influence recipient cells and modify their behavior. MicroRNAs are master regulators of cellular development. They regulate cell fate decisions such as lineage commitment and differentiation but also self-renewal of HSPCs \[[@pone.0128231.ref011],[@pone.0128231.ref012]\]. It has even been shown that modulation of certain miRNAs promotes *in vitro* expansion of HSPCs \[[@pone.0128231.ref013]--[@pone.0128231.ref015]\] or at least maintenance of a more primitive immunophenotype during *in vitro* cultivation \[[@pone.0128231.ref016]\]. Therefore, it is conceivable that specific miRNAs contribute to activation of the stem cell pool after high dose chemotherapy and HSCT.

Alternatively, metabolites might be relevant for regulation of stem cell function. They are intermediates and products of metabolism of usually less than 1 kDa in size. Recently, it has been shown that the niche regulates self-renewal of HSPCs via retinoic acid signaling \[[@pone.0128231.ref017]\]. Furthermore, there are studies indicating that HSPC quiescence is tightly regulated by the metabolic microenvironment \[[@pone.0128231.ref018],[@pone.0128231.ref019]\]. Chemotherapy induces metabolic changes such as down-regulation of extracellular glutathione peroxidase and up-regulation of gamma-tocopherol concentration in patient serum \[[@pone.0128231.ref020]\]. Metabolomics---the quantitative analysis of metabolite profiles e.g. by mass-spectrometry---is ideally suited to identify relevant factors and this has been used for various cancer types. For example, metabolomics of colorectal cancer patients led to identification of circulating metabolites with significant changes in liver-only metastases and with extrahepatic metastases \[[@pone.0128231.ref021]\]. Other metabolites can be used as potential biomarker to predict response to neoadjuvant chemotherapy in breast cancer patients \[[@pone.0128231.ref022]\]. Furthermore, certain metabolites can influence the expression of miRNAs \[[@pone.0128231.ref023]\] and *vice versa*, and it has been shown that miRNAs can regulate metabolic pathways \[[@pone.0128231.ref024],[@pone.0128231.ref025]\].

So far, it is still unclear if specific miRNAs or metabolites are relevant for activation of the hematopoietic stem cell pool. To this end, we performed a comparative analysis of patient serum before and after chemotherapy with particular focus on miRNAs and metabolites.

Material and Methods {#sec002}
====================

Serum samples in the course of autologous HSCT {#sec003}
----------------------------------------------

Ten mL of peripheral blood were collected from patients with lymphoma, acute myeloid leukemia (AML), multiple myeloma (MM) and healthy controls after written consent as described before \[[@pone.0128231.ref004]\]. Isolation of serum samples and the study were specifically approved by the Ethic Committee of RWTH Aachen University (Permit Number: EK155/09). Blood samples taken before chemotherapy (BC) and during leukopenia after HSCT (AC) were transferred into a 15 mL tube (Greiner, Kremsmünster, Austria), agitated horizontally at 37°C for 1 h to allow coagulation, then incubated upright at 4°C for 4 h and finally centrifuged at 840 x g for 15 min \[[@pone.0128231.ref026]\]. Serum supernatant was aliquoted and stored at -80°C until use. Further information on serum samples and patients is provided in Tables A, B, C and D in [S1 File](#pone.0128231.s001){ref-type="supplementary-material"}.

Isolation of hematopoietic stem and progenitor cells and of mesenchymal stromal cells {#sec004}
-------------------------------------------------------------------------------------

CD34^+^ cells were isolated from fresh umbilical cord blood after written consent. Isolation of CD34^+^ cells and the study were specifically approved by the Ethic Committee of RWTH Aachen University (Permit Number: EK187/08). For antagomiR experiments we used CD133^+^ cells, which were isolated from cord blood from DKMS Nabelschnurblutbank (Dresden, Germany). Isolation of CD133^+^ cells from fresh cord blood (DKMS Nabelschnurblutbank, Dresden, Germany) and the study were specifically approved by the local Ethics Committee of the Ärztekammer Nordrhein (Permit Number: EK103/2011). In brief, mononuclear cells were separated by density gradient centrifugation and CD34^+^ or CD133^+^ cells were enriched using MicroBead Kits according to the manufacturer's instructions (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) \[[@pone.0128231.ref027]\]. For co-culture conditions, MSCs were isolated from the *caput femoris* after the patient's written consent and cultivated as described before \[[@pone.0128231.ref004],[@pone.0128231.ref028]\]. Isolation of MSCs from bone marrow and the study were specifically approved by the Ethic Committee of RWTH Aachen University (Permit Number: EK128/09). MSCs were seeded as feeder cells between passages 3 to 6 (10 to 15 population doublings).

Culture conditions and expansion of HSPCs with serum supplementation {#sec005}
--------------------------------------------------------------------

Hematopoietic stem and progenitor cells were expanded in 24-well plates (Nunc) in StemSpan serum-free expansion medium (Stem Cell Technologies, Grenoble, France) either without stromal support or upon co-culture on a confluent layer of MSCs. Culture medium was supplemented in parallel with 10% of each serum sample (BC or AC) \[[@pone.0128231.ref004]\]. In order not to falsify potential serum effects on HSPCs, no further cytokines were supplemented to the culture medium.

Analysis of cell division history {#sec006}
---------------------------------

Freshly isolated HSPCs were labeled with carboxyfluorescein diacetate N-succinimidyl ester (CFSE; Sigma-Aldrich) or the CellTrace Violet Cell Proliferation Kit (Violet Dye, Life Technologies, Carlsbad, CA, 92008, USA) to monitor cell divisions \[[@pone.0128231.ref027]\]. The fluorescent dye thereby binds to protein residues resulting in a homogenously stained cytoplasm. The fluorescent dye is then equally distributed to the daughter cells within each cell division (higher proliferation entails lower fluorescence intensity). In brief, cells were washed in PBS and then stained with CFSE at a final concentration of 2.5 μM in PBS with 0.1% fetal calf serum (FCS; PAA Laboratories, Cölbe, Germany) for 10 min at 37°C. Violet Dye was used at a final concentration of 1.67 μM in PBS. The staining reaction was stopped with ice cold PBS (PAA) with 10% FCS for 5 min on ice followed by three washing steps with PBS. HSPCs were then expanded and after four to seven days; CFSE or Violet Dye intensity was measured together with immunophenotype by flow cytometry using a FACS Canto II (BD) or a MACSQuant Analyzer 10 (Miltenyi Biotec).

Immunophenotypic analysis {#sec007}
-------------------------

CD34^+^ cells were washed in PBS, stained with CD34-allophycocyanin (APC; Becton Dickinson, San Jose, CA, USA \[BD\], clone 8G12), CD38-PE (BD, clone HB-7) and CD45-V500 (BD, clone HI30) in a dilution of 1:200 and analyzed using a FACS Canto II (BD) running FACS Diva software (BD). Further analysis was performed using WinMDI software (WinMDI 2.8; The Scripps Institute, San Diego, CA, USA). Discrimination between MSCs and HSPCs was possible by forward scatter, side scatter, propidium iodide (PI) staining and CFSE-staining. CD133^+^ cells, which were used for antagomiR experiments, were stained with CD133/2-PE (clone 293C3) and CD34-APC (clone AC136) according to the manufacturer's protocol (Miltenyi Biotec). Analysis was performed with the MACSQuant Analyzer 10 and the MACSQuant Software (Miltenyi Biotec).

miRNA profiling {#sec008}
---------------

Frozen serum samples were thawed at room temperature. Total RNA was extracted from 500 μL of serum using TRIzol LS Reagent (Life technologies, Darmstadt, Germany) and the miRNeasy mini kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. The RNA sample volume was reduced in a Speed Vac to a final volume of 1 μL and labeled and hybridized using the Human microRNA Microarray Kit (Rel16.0, Agilent Technologies, Santa Clara, CA, USA) according to the manufacturer's protocol. The detailed hybridization protocol and raw data are provided in NCBI\'s Gene Expression Omnibus (GEO, Series accession number GSE57570). For statistical analysis, signal intensities were normalized to the array median, log2 transformed and subjected to Student's paired t-test. For heat map presentation, the Multiple Experiment Viewer tool version 4.9.0 (Dana-Farber Cancer Institute, Boston, MA, USA) was used. Prediction of miRNA targets was performed using TargetScan \[[@pone.0128231.ref029]\]. The predicted targets were classified in Gene Ontology categories of molecular function to estimate relevant biological processes. As background for the analysis, the probe set of the Agilent Whole Human Genome Oligo Microarray (8x60k) was chosen. Term enrichment relative to the expected background distribution was scored using Fisher's Exact test with Benjamini--Hochberg correction.

qRT-PCR of miRNAs {#sec009}
-----------------

Total RNA was extracted from 500 μL of serum, reduced to a final volume of 6 μL and subsequently used for reverse transcription applying the miScript II RT Kit (Qiagen). For Real-Time PCR, the miScript SYBR Green PCR Kit and miScript Primer Assay (Hs_miR-320_3) were used according to the manufacturer's protocol (miScript PCR System, Qiagen). PCR was performed in an ABI 7900HT Fast Real-Time PCR System (Life technologies).

Inhibition of miRNA-320c activity in HSPCs {#sec010}
------------------------------------------

For inhibition of miRNA-320c activity, we used cholesterol-modified antagomiRs targeting miRNA-320c (anta-320c, `ACCCUCUCAACCCAGCUUUU`) or a non-targeting control (anta-Neg). AntagomiRs were synthesized by Miltenyi Biotec according to Krützfeld et al. \[[@pone.0128231.ref030]\]. CD133^+^ cells were stained with Violet Dye, cultivated overnight and then electroporated with antagomiRs using the CD34 Cell Nucleofector Kit and Nucleofector II device from Amaxa (Lonza, Cologne, Germany) according to the manufacturer's protocol. We used 7 to 9 x 10^4^ cells per sample and a final antagomiR concentration of 3 μM. Electroporation efficiency was assessed using 2 μM of non-targeting siRNA labeled with AlexaFluor 488 (AF488-siRNA) or 2.4 μg of a GFP-encoding mRNA. After electroporation, cells were cultured overnight in 500 μL StemSpan serum-free expansion medium supplemented with 10 ng/mL human stem cell factor (SCF), 20 ng/mL human thrombopoietin (TPO), 10 ng/mL human fibroblast growth factor 1 (FGF-1, all from Miltenyi Biotec), 10 μg/mL heparin (Ratiopharm GmbH, Ulm, Germany) and penicillin / streptomycin (PAA) and then re-seeded in 96-well U-bottom plates (BD) at 5 x 10^3^ cells per well in 150 μL StemSpan serum-free expansion medium supplemented with 10% human AB-serum (Dunn Labortechnik GmbH, Asbach, Germany) without further cytokines. Violet Dye intensity and immunophenotype were analyzed by flow cytometry (MACSQuant Analyzer 10) four days after electroporation.

Metabolomics {#sec011}
------------

Biomarkers in serum samples were analyzed in cooperation with Metabolon Inc. (Durham, NC, USA). In brief, biochemical profiling was performed using multiple platform mass spectrometry technology consisting of liquid chromatography/mass spectrometry (LC/MS), gas chromatography/mass spectrometry (GC/MS) and accurate mass determination and MS/MS fragmentation (LC/MS) to cover a broad profile of 297 small molecule metabolites. Analysis and interpretation of data was performed by Metabolon Inc. Metabolites were identified by automated comparison and spectra fitting to a chemical standard library of experimentally derived spectra as previously described \[[@pone.0128231.ref031]--[@pone.0128231.ref033]\]. Missing values were imputed by the lowest measured value to avoid bias from different detection levels. Data were then median normalized, log2 transformed and subjected to paired two-sited Student's t-test analysis. Further analysis and heatmap presentation was performed with the TIGR MeV tool (Dana-Farber Cancer Institute, Boston, MA, USA).

Supplementation of metabolites {#sec012}
------------------------------

Hematopoietic stem and progenitor cells were expanded in 24-well plates (Nunc) in StemSpan serum free expansion medium (Stem Cell Technologies, Grenoble, France) either without stromal support or on a confluent layer of MSCs as described above. Culture medium was supplemented with 10 ng/mL stem cell factor (SCF; PeproTech GmbH, Hamburg, Germany), 20 ng/mL thrombopoietin (TPO; PeproTech), 10 ng/mL fibroblast growth factor 1 (FGF-1; PeproTech) and 10 μg/mL heparin (Roche GmbH, Mannheim, Germany) as previously described \[[@pone.0128231.ref028]\]. Furthermore, metabolites were added in a range of different concentrations that in most cases presumably cover physiological concentrations: gamma-tocopherol (Sigma Aldrich; 10 μM to 1 mM; physiological concentration: 0--40 μM, \[[@pone.0128231.ref034]\]), lactate (Roth; 1--100 μM; physiological concentrations: 0.3--1.3 μM \[[@pone.0128231.ref035]\]), alanine (Roth; 1--100 μM), uridine (Roth; 1--100 μM; physiological concentrations: 5.2 μM \[[@pone.0128231.ref036]\]), taurocholic acid sodium salt hydrate (Sigma Aldrich; 1--100 μM; total bile acid concentration range: 3.75--4.17 μM \[[@pone.0128231.ref037]\]), L-glutamic acid monosodium salt hydrate (Sigma Aldrich; 1--100 mM), N^G^,N^G^-dimethylarginine dihydrochloride (Sigma Aldrich; 1--100 μM; physiological concentrations: 6,8 μM \[[@pone.0128231.ref038]\]), tert-butyl(R)-2-hydroxybutyrate (Sigma Aldrich; 10 μM---1 mM; physiological concentrations: 31.3 μM \[[@pone.0128231.ref039]\]) and 12(S)-Hydroxy-(5Z,8Z,10E,14Z)-eicosatetraenoic acid (Sigma Aldrich; 10 nM---1 μM) were supplemented to the culture medium as indicated in the text.

Colony forming unit assay {#sec013}
-------------------------

Colony forming unit (CFU) potential was determined to estimate expansion of HSPCs with serum before and after chemotherapy as we have described before \[[@pone.0128231.ref004]\] and to estimate culture expansion of HSPCs upon treatment with metabolites or antagomiRs. 12,500 CD34^+^ cells were grown in StemSpan medium supplemented with SCF, TPO, FGF-1 and heparin as described above. Metabolites were added in the highest concentration of the previous tests. AntagomiR-electroporated cells were cultured as described above. After seven days, the progeny of HSPCs was re-seeded in different dilutions (1:10, 1:100 and 1:1000 dilution) in 24-well culture dishes with 500 μL methylcellulose medium per well (HSC-CFU lite with EPO; Miltenyi Biotec). After two additional weeks of incubation with methylcellulose medium, granulocyte (CFU-G), macrophage (CFU-M) and erythrocyte colonies (CFU-E) were counted according to the manufacturer's instructions.

Statistical analysis {#sec014}
--------------------

Unless stated otherwise we adopted the Student's t-test (paired analysis if applicable) to estimate statistical significance. A P-value of either ≤ 0.05 or ≤ 0.01 was considered as statistically significant (as indicated in the text).

Results {#sec015}
=======

Serum after chemotherapy stimulates proliferation of HSPCs {#sec016}
----------------------------------------------------------

Serum was taken from ten patients before chemotherapy (BC) and after chemotherapy (AC, see Table A in [S1 File](#pone.0128231.s001){ref-type="supplementary-material"}). These serum samples were then supplemented in parallel to culture media for *in vitro* expansion of HSPCs (always 10% serum). CD34^+^ cells from umbilical cord blood were stained with CFSE to monitor cell division. After five days of culture, flow cytometric analysis revealed that serum samples taken during neutropenia (AC) enhanced proliferation of HSPCs significantly as compared to corresponding samples taken before chemotherapy (BC) ([Fig 1A](#pone.0128231.g001){ref-type="fig"}; five independent experiments, each of them with serum samples of all 10 patients; P = 2.74 x 10^--8^). This growth-promoting effect was not observed under co-culture with mesenchymal stromal cells (MSCs) which might be attributed to the massive growth-promoting effect of the supportive cellular environment (Fig. A in [S1 File](#pone.0128231.s001){ref-type="supplementary-material"}). Furthermore, serum after chemotherapy maintained higher levels of CD34 as determined by flow cytometry ([Fig 1B](#pone.0128231.g001){ref-type="fig"})---despite the fact that increased proliferation is usually associated with loss of CD34 \[[@pone.0128231.ref027]\]. The same effect was also observed under co-culture conditions with MSCs (Fig. A in [S1 File](#pone.0128231.s001){ref-type="supplementary-material"}). Notably, serum-free controls revealed much higher CD34 expression than serum BC or AC and this might also be attributed to lower proliferation rates. No significant differences were detected in serum BC *versus* AC with regard to CD38 and CD45 expression either with or without co-culture with MSCs even though there were some changes as compared to controls without serum additives (Fig [1C](#pone.0128231.g001){ref-type="fig"} and [1D](#pone.0128231.g001){ref-type="fig"}; and Fig. A in [S1 File](#pone.0128231.s001){ref-type="supplementary-material"}). Subsequently, we tested if blood parameters---such as cell counts of leucocytes, thrombocytes, erythrocytes and hemoglobin---correlate with *in vitro* proliferation of HSPC. This analysis was performed separately for BC serum (Fig. B in [S1 File](#pone.0128231.s001){ref-type="supplementary-material"}) and AC serum samples (Fig. B in [S1 File](#pone.0128231.s001){ref-type="supplementary-material"}). After chemotherapy, particularly serum of anemic patients significantly stimulated HSPC proliferation as compared to non-anemic samples (erythrocyte count: P = 0.046, hemoglobin level: P = 0.009, Pearson correlation). Subsequently, we determined CFU potential as a surrogate assay to estimate expansion of HSPCs under the influence of either BC or AC serum. CD34^+^ cells were cultured for seven days with 10% serum supplements and then re-seeded in methylcellulose medium for two additional weeks. Overall, formation of CFU-G, CFU-GM and CFU-GEMM was significantly higher in AC serum ([Fig 1E](#pone.0128231.g001){ref-type="fig"}) \[[@pone.0128231.ref004]\].

![Impact of serum on HSPC proliferation, immunophenotype, and CFU potential.\
HSPCs were stained with CFSE and *in vitro* cultured for five days with 10% serum supplementation. Serum was derived from patients before (BC) and after (AC) chemotherapy. As control (Ctr.) cells were cultured without serum. (A) CFSE mean intensity (lower signal intensity indicates higher proliferation rate), as well as mean fluorescence intensities of (B) CD34, (C) CD38, and (D) CD45 were then determined via flow cytometry (intensities were normalized to the corresponding control; n = 5). (E) HSPCs were cultured with BC or AC serum for seven days and were then re-seeded in methylcellulose medium. After two weeks numbers of burst forming unit erythrocyte (BFU-E), colony forming unit erythrocyte (CFU-E), granulocyte (CFU-G), macrophage (CFU-M), granulocyte and macrophage (CFU-GM) as well as granulocyte, erythrocyte, megakaryocyte and macrophage (CFU-GEMM) were counted. (n = 2). \*P \< 0.05; \*\*P \< 0.01; Error bars represent SD.](pone.0128231.g001){#pone.0128231.g001}

Differentially expressed miRNAs in serum samples before and after chemotherapy {#sec017}
------------------------------------------------------------------------------

MicroRNAs might be relevant for the stimulatory effect of serum after chemotherapy, and therefore we compared miRNA profiles in serum samples from nine patients before and after therapy (Table B in [S1 File](#pone.0128231.s001){ref-type="supplementary-material"}). Overall, the number of detected miRNAs decreased significantly in serum taken after chemotherapy ([Fig 2A](#pone.0128231.g002){ref-type="fig"}) and signal intensities decreased as compared to serum before chemotherapy ([Fig 2B](#pone.0128231.g002){ref-type="fig"}). The global miRNA expression level correlated significantly with leucocyte numbers (Fig. C in [S1 File](#pone.0128231.s001){ref-type="supplementary-material"}; P = 0.0004), and this was also true for known hematopoietic miRNAs such as miRNA-486-5p, miRNA-22 and miRNA-150 \[[@pone.0128231.ref040],[@pone.0128231.ref041]\]. This may indicate that most of the observed changes in miRNA expression are due to neutropenia after HSCT. Taking this into consideration, the microarray data were normalized to the array median. Using paired t-test, we found 23 miRNAs to be significantly differentially expressed in BC serum *versus* AC serum (P ≤ 0.01, [Fig 2C](#pone.0128231.g002){ref-type="fig"}). MicroRNA-320c (P = 0.0002), miRNA-1275 (P = 0.0005), and miRNA-3663-3p (P = 0.0006) revealed the most significant differences. MicroRNA-320c and miRNA-1275 were increased in samples before chemotherapy, whereas miRNA-3663-3p was higher after chemotherapy ([Fig 2D](#pone.0128231.g002){ref-type="fig"}). These miRNAs were also amongst the most significantly differentially expressed genes when we compared AC *versus* BC serum samples separately for AML and MM patients, indicating that these changes seem to be independent from disease and treatment (Fig. D in [S1 File](#pone.0128231.s001){ref-type="supplementary-material"}). Furthermore, the results were exemplarily validated by quantitative real-time PCR (qRT-PCR) of miRNA-320c ([Fig 2E](#pone.0128231.g002){ref-type="fig"})---a miRNA that is predicted to target a broad range of developmentally relevant genes (Fig. E in [S1 File](#pone.0128231.s001){ref-type="supplementary-material"}).

![Differential miRNA expression in serum before and after chemotherapy.\
(A) Bar chart displaying the average number of detected miRNAs in serum samples of patients before chemotherapy (BC; n = 9), after chemotherapy (AC; n = 9), and of healthy controls (n = 7). Error bars represent SD, \*\*P = 0.004. (B) Median signal intensities AC *versus* BC (n = 9). Significantly differentially expressed microRNAs after normalization are marked in blue; the three most significant miRNAs miRNA-320c, miRNA-1275 and miRNA-3663-3p are marked in red. Data points on the x-axis represent 163 miRNAs that are exclusively detected in BC serum. No miRNAs were exclusively detected in AC serum. (C) Heat map of significantly differentially expressed miRNAs in patient samples BC and AC (P ≤ 0.01, paired t-test). Displayed is the log2-transformed ratio of the normalized signal intensities *versus* median signal intensity of BC serum. (D) The three most significantly differentially expressed miRNAs showed consistent expression patterns in serum of all analyzed patients (Ratio of normalized signal intensities in serum AC *versus* BC). (E) qRT-PCR confirmed increased expression of miRNA-320c in serum BC compared to AC. Fold change of miRNA expression is shown as mean of triplicates for three patient sample pairs. Error bars represent SD.](pone.0128231.g002){#pone.0128231.g002}

Inhibition of miRNA-320c {#sec018}
------------------------

Circulating miRNAs can be taken up by recipient cells \[[@pone.0128231.ref008]\] and therefore we reasoned that decreased serum levels of miRNAs may impact on hematopoietic regeneration. To further address the functional relevance of specific miRNAs, we exemplarily silenced miRNA-320c in HSPCs. Since miRNA-320c is down-regulated in AC serum, we hypothesized that hematopoiesis supportive effects might be mimicked by electroporation with the corresponding antagomiR (anta-320c). AntagomiRs are chemically engineered oligonucleotides that efficiently and persistently silence endogenous miRNAs \[[@pone.0128231.ref042]\]. Electroporation of anta-320c resulted in a significantly increased proliferation of HSPCs as compared to control cells (anta-Neg) (Fig. F in [S1 File](#pone.0128231.s001){ref-type="supplementary-material"}). However, CD34 expression decreased upon treatment with anta-320c and the number of CFUs was not significantly affected (Fig. F in [S1 File](#pone.0128231.s001){ref-type="supplementary-material"}). Efficiency of electroporation was determined in previous optimization experiments (Fig. F in [S1 File](#pone.0128231.s001){ref-type="supplementary-material"}): using a fluorescently labeled, non-targeting siRNA (AF488-siRNA) or a GFP mRNA, we obtained 90.3 and 96.8% of fluorescent cells, respectively, indicating that the delivery of RNA molecules was highly efficient---and therefore we expect that the observed effects of anta-320c are due to knockdown of the corresponding miRNA. Thus, inhibition of miRNA-320c is not sufficient to mimic the hematopoiesis supportive effects of serum taken under neutropenia.

Metabolomic changes after chemotherapy {#sec019}
--------------------------------------

Subsequently, we analyzed metabolite profiles in serum BC *versus* AC using multiple mass spectrometry technology. The identified dataset comprises a total of 297 named biochemicals. Upon log transformation and imputation with minimum observed values for each compound, 47 metabolites differed significantly between serum BC and AC ([Fig 3](#pone.0128231.g003){ref-type="fig"}; n = 7; paired t-test; P ≤ 0.01; and Table C in [S1 File](#pone.0128231.s001){ref-type="supplementary-material"}): 44 metabolites were less abundant after chemotherapy such as citrulline, urea cycle components, proline, 4-hydroxyproline, the dipeptide proline-hydroxyproline, choline, glycerol-3-phosphate, glycerophosphorylcholine many lysolipids, an oxidized form of arachidonic acid (12-HETE), and theobromine. Only three metabolites revealed higher abundance upon chemotherapy: 2-hydroxybutyrate, taurocholenate sulfate and pantoprazole. Overall, none of the tested metabolites clearly correlated with cell counts (leukocytes, thrombocytes, erythrocytes, and hemoglobin; Figs. G, H, I and J in [S1 File](#pone.0128231.s001){ref-type="supplementary-material"}) -- except for uridine, which moderately increases with leucocyte numbers (P = 0.038, Pearson rank correlation)---indicating that changes in metabolites not solely attributed to the changing composition of blood cells. In fact, pantoprazole was given to the patients as a stomach protection after chemotherapy whereas lower concentration of theobromine is related to changes in the patient's nutrition upon HSCT. This exemplifies that there are significant changes in metabolite profiles of serum after chemotherapy which can be successfully tracked by the metabolomics approach.

![Heat map of significantly differentially detected metabolites.\
Seven samples before (BC) and after chemotherapy (AC) were analyzed with regard to their metabolite composition. 44 metabolites were significantly down-regulated and three were up-regulated after chemotherapy (Multiple Myeloma (MM), non-Hodgekin Lymphoma follicular (NHL); P ≤ 0.01; paired t-test).](pone.0128231.g003){#pone.0128231.g003}

Functional testing of various metabolites on HSPC *in vitro* expansion {#sec020}
----------------------------------------------------------------------

To further analyze the functional relevance of specific metabolites, we tested their effect on *in vitro* culture of HSPCs. CD34^+^ HSPCs were isolated from CB, stained with CFSE and cultured either with or without stromal support. Culture medium was supplemented with 12-HETE, glutamic acid, gamma-tocopherol, lactate, uridine, alanine, dimethylarginine, 2-hydroxybutyrate and taurocholic acid in three concentrations that were expected to cover the physiological concentrations ([Fig 4A](#pone.0128231.g004){ref-type="fig"}). After five days, cells were analyzed by FACS and residual CFSE-staining as well as expression of CD34 and CD45 were determined. Several metabolites increased proliferation particularly at lower concentrations, but these results hardly reached statistical relevance. Loss of CD34 expression correlated with faster cell proliferation. For example, addition of 1 mM or 10 mM glutamic acid lead to significantly reduced CFSE intensity and expression of CD34 compared to control samples without metabolite addition (Fig [4A](#pone.0128231.g004){ref-type="fig"}--[4C](#pone.0128231.g004){ref-type="fig"}). In contrast, CD45 expression was hardly influenced. Even in co-culture with MSCs the metabolites hardly influenced proliferation and surface marker expression (Fig. K in [S1 File](#pone.0128231.s001){ref-type="supplementary-material"}).

![Proliferation and immunophenotypic analysis upon addition of metabolites.\
HSPCs were stained with CFSE and *in vitro* cultured for five days with supplementation of metabolites. These experiments were performed in parallel using three different concentrations for each metabolite as indicated. (A) CFSE intensity as well as (B) expression of CD34 and (C) CD45 were then determined via flow cytometry and normalized to the corresponding control. Error bars represent SD. (D) Alternatively, HSPCs were cultured for seven days in parallel with each of the metabolites and then reseeded in methylcellulose medium. After two additional weeks the numbers of erythrocyte (CFU-E), granulocyte (CFU-G) and macrophage (CFU-M) colonies were counted. Error bars represent SEM, \*P ≤ 0.05, \*\*P ≤ 0.01, \*\*\*P ≤ 0.001; n = 3.](pone.0128231.g004){#pone.0128231.g004}

Subsequently, we determined colony forming unit (CFU) potential as a surrogate assay to estimate expansion of HSPCs. CD34^+^ cells were cultured for seven days with each of the nine metabolites. Cells were then reseeded in methylcellulose medium, and after 12 to 14 days granulocyte (CFU-G), macrophage (CFU-M) and erythrocyte colonies (CFU-E) were counted. Addition of 100 μM taurocholic acid significantly reduced CFU-E rate compared to controls without addition of metabolites, whereas no significant impact on colony formation rate of the other eight tested metabolites was detected ([Fig 4D](#pone.0128231.g004){ref-type="fig"}).

Discussion {#sec021}
==========

Hematopoietic stress after chemotherapy necessitates tight regulation of self-renewal and differentiation of HSPCs. Our results support the notion that this is associated with systemically released factors, which are also active under *in vitro* culture conditions. In this study, we considered patients of different disease background and therapeutic regimen---e.g. myeloid leukemia patients undergoing cytarabine based consolidation *versus* multiple myeloma patients treated with high-dose melphalan therapy and autologous HSCT. Such parameters are certainly relevant confounders, which need to be further addressed by larger datasets. Further relevant factors may be parenteral nutrition and the consecutive inflammatory milieu. However, our results indicate similar hematopoiesis supportive activity, and similar changes in miRNA and metabolites were observed in our clinically heterogeneous patient cohort. Notably, most of the miRNAs and metabolites which revealed significant changes upon chemotherapy were down-regulated. Initially, we anticipated that increased self-renewal is associated with up-regulation of specific factors. Alternatively, it is also conceivable that stem cell function is suppressed under steady state conditions by specific molecules which are down-regulated during hematopoietic stress.

Recently, we have developed mathematical models for hematopoietic regeneration upon autologous stem cell transplantation \[[@pone.0128231.ref043],[@pone.0128231.ref044]\] and for disease development of myelodysplastic syndromes (MDS) \[[@pone.0128231.ref045]\]. All of these studies postulated feedback signals acting on proliferation and differentiation of the stem cell pool, and all of them were in line with experimental validation using serum samples for *in vitro* culture of HSPCs. Thus, there is evidence that factors involved in this regulatory mechanism are not only acting locally in the bone marrow niche, but also at systemic level, but however, the questions remain which molecules govern this process.

Our current study provides evidence that the miRNA-landscape changes in the course of chemotherapy. Overall, the miRNA-levels decline in AC serum. This may partly be attributed to reduction of disease-specific miRNAs which have been described in various malignant disorders including AML, MM \[[@pone.0128231.ref046]\], and acute lymphoblastic leukemia (ALL) \[[@pone.0128231.ref047]\]. This might also explain why in tendency miRNA-levels in serum BC were higher than in healthy controls. However, there is evidence that most of the circulating miRNAs originate from blood cells and that perturbations in blood cell counts can alter the miRNA expression profile in serum \[[@pone.0128231.ref048]\]. This is in line with our observed correlation of leucocyte counts and global miRNA levels including typical hematopoietic miRNAs such as miRNA-486-5p. Therefore, we had to normalize miRNA profiles to identify specific miRNAs with significant changes. Down-regulation of miRNA-320c and miRNA-1275 after chemotherapy might indicate that these miRNAs have a negative effect on proliferation.

Recently, it has been demonstrated that the miRNA-320 family suppresses stem cell-like characteristics in prostate cancer cells by down-regulating the Wnt/beta-catenin signaling pathway \[[@pone.0128231.ref049]\]---a pathway which is also of central importance for regulation of self-renewal and proliferation in hematopoietic stem cells \[[@pone.0128231.ref050],[@pone.0128231.ref051]\]. Furthermore, miRNA-320 targets the transferrin receptor CD71 in the human leukemia cell line HL-60, thereby inhibiting proliferation \[[@pone.0128231.ref052]\]. We could show that inhibition of miRNA-320c activity using an antagomiR has a growth-promoting effect on HSPCs---yet the mean CD34 expression decreased as compared to controls. Therefore, it appears to be rather unlikely that down-regulation of miRNA-320c is the only relevant factor for increased proliferation of HSPCs because many other miRNAs were also changing in AC serum. If down-regulation of these miRNAs is functionally relevant, then they probably act in concert.

Beside changes in the miRNA landscape, we identified 47 metabolites that were significantly changed in AC serum, and again most of them were down-regulated. Down-regulation of proline, 4-hydroxyproline and proline-hydroxyproline may reflect changes in tissue and extracellular matrix remodeling \[[@pone.0128231.ref053],[@pone.0128231.ref054]\]. Furthermore, decrease of choline, glycerol-3-phosphate, glycerophosphorylcholine, lysolipids, and of the arachidonic acid oxidation product 12-HETE may indicate decreased phospholipid turnover after chemotherapy \[[@pone.0128231.ref055]\]. AC serum showed significantly reduced levels gamma-tocopherol, a form of vitamin E. Moreover, it has also been described that gamma-tocopherol increases prior to HSCT \[[@pone.0128231.ref020]\]. Incubation of HSPCs with 10 μM gamma-tocopherol slightly increased proliferation of HSPCs, although it has been suggested that gamma-tocopherol inhibits cell cycle progression in cancer by down-regulation of cyclins \[[@pone.0128231.ref056]\]. Thus, these effects appear to be specific for culture conditions and cell types. 2-Hydroxybutyrate was found to be an early biomarker of both insulin resistance and impaired glucose regulation \[[@pone.0128231.ref057]\]. Elevated concentrations of bile acids like taurocholic acid impair proliferation and increase apoptosis in Jurkat cells \[[@pone.0128231.ref058]\]. Our results with specific metabolites did not reveal consistent and pronounced effects on proliferation, immunophenotype or CFU-potential of HSPCs. In fact, several results partly contradict each other---e.g. taurocholic acid, which was increased after chemotherapy in patient serum, moderately reduced the CFU-E rate, although higher proliferation was observed with serum of rather anemic patients. Thus, none of the metabolites appears to be an exclusive regulator of hematopoiesis---probably a network of factors is needed to recapitulate the hematopoiesis supportive effects of serum during aplasia.

Until now, research has mainly focused on characterization of HSPCs and methods for their *in vitro* expansion to obtain sufficient cell numbers for HSCT \[[@pone.0128231.ref059]\]. Mechanisms for the activation of stem cell function in the course of chemotherapy have hardly been addressed. Therefore, a better understanding of the physiologic mechanisms that recruit the stem cell pool into action may provide new perspectives for regenerative medicine without requirement of transplantation. Our study demonstrates that aplasia after high dose chemotherapy is also associated with significant changes in miRNA and metabolite profiles. Most of them were less abundant after chemotherapy and there was no clear evidence that one of them is playing a unique role for activation of the stem cell pool. It is however conceivable that these factors act in concert with other regulatory factors. The hematopoietic stem cell niche provides a very complex environment which is modulated by growth factors, miRNAs, and metabolites---even though so far none of them seems to govern hematopoiesis *per se*.
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